Sudden unexpected death in epilepsy in patients treated with brain-responsive neurostimulation

Orrin Devinsky, Daniel Friedman, Robert B. Duckrow, Nathan B. Fountain, Ryder P. Gwinn, James W. Leiphart, Anthony M Murro, Paul C. Van Ness

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: To study the incidence and clinical features of sudden unexpected death in epilepsy (SUDEP) in patients treated with direct brain-responsive stimulation with the RNS System. Methods: All deaths in patients treated in clinical trials (N = 256) or following U.S. Food and Drug Administration (FDA) approval (N = 451) through May 5, 2016, were adjudicated for SUDEP. Results: There were 14 deaths among 707 patients (2208 postimplantation years), including 2 possible, 1 probable, and 4 definite SUDEP events. The rate of probable or definite SUDEP was 2.0/1000 (95% confidence interval [CI] 0.7-5.2) over 2036 patient stimulation years and 2.3/1000 (95% CI 0.9-5.4) over 2208 patient implant years. Stored electrocorticograms around the time of death were available for 4 patients with probable/definite SUDEP and revealed the following: frequent epileptiform activity ending abruptly (n = 2), no epileptiform activity or seizures (n = 1), and an electrographic and witnessed seizure with cessation of postictal electrocorticography (ECoG) activity associated with apnea and pulselessness (n = 1). Significance: The SUDEP rate of 2.0/1000 patient stimulation years among patients treated with the RNS System is favorable relative to treatment-resistant epilepsy patients randomized to the placebo arm of add-on drug studies or with seizures after resective surgery. Our findings support that treatments that reduce seizures reduce SUDEP risk and that not all SUDEPs follow seizures.

Original languageEnglish (US)
Pages (from-to)555-561
Number of pages7
JournalEpilepsia
Volume59
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

Sudden Death
Epilepsy
Brain
Seizures
Confidence Intervals
Drug Approval
Apnea
Cohort Studies
Placebos
Clinical Trials
Food
Therapeutics
Pharmaceutical Preparations

Keywords

  • brain stimulation
  • closed-loop
  • neuromodulation
  • partial seizures
  • sudden unexpected death in epilepsy

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Devinsky, O., Friedman, D., Duckrow, R. B., Fountain, N. B., Gwinn, R. P., Leiphart, J. W., ... Van Ness, P. C. (2018). Sudden unexpected death in epilepsy in patients treated with brain-responsive neurostimulation. Epilepsia, 59(3), 555-561. https://doi.org/10.1111/epi.13998

Sudden unexpected death in epilepsy in patients treated with brain-responsive neurostimulation. / Devinsky, Orrin; Friedman, Daniel; Duckrow, Robert B.; Fountain, Nathan B.; Gwinn, Ryder P.; Leiphart, James W.; Murro, Anthony M; Van Ness, Paul C.

In: Epilepsia, Vol. 59, No. 3, 01.03.2018, p. 555-561.

Research output: Contribution to journalArticle

Devinsky, O, Friedman, D, Duckrow, RB, Fountain, NB, Gwinn, RP, Leiphart, JW, Murro, AM & Van Ness, PC 2018, 'Sudden unexpected death in epilepsy in patients treated with brain-responsive neurostimulation', Epilepsia, vol. 59, no. 3, pp. 555-561. https://doi.org/10.1111/epi.13998
Devinsky O, Friedman D, Duckrow RB, Fountain NB, Gwinn RP, Leiphart JW et al. Sudden unexpected death in epilepsy in patients treated with brain-responsive neurostimulation. Epilepsia. 2018 Mar 1;59(3):555-561. https://doi.org/10.1111/epi.13998
Devinsky, Orrin ; Friedman, Daniel ; Duckrow, Robert B. ; Fountain, Nathan B. ; Gwinn, Ryder P. ; Leiphart, James W. ; Murro, Anthony M ; Van Ness, Paul C. / Sudden unexpected death in epilepsy in patients treated with brain-responsive neurostimulation. In: Epilepsia. 2018 ; Vol. 59, No. 3. pp. 555-561.
@article{52ddec66f7b14d7ba30eab67a401315e,
title = "Sudden unexpected death in epilepsy in patients treated with brain-responsive neurostimulation",
abstract = "Objective: To study the incidence and clinical features of sudden unexpected death in epilepsy (SUDEP) in patients treated with direct brain-responsive stimulation with the RNS System. Methods: All deaths in patients treated in clinical trials (N = 256) or following U.S. Food and Drug Administration (FDA) approval (N = 451) through May 5, 2016, were adjudicated for SUDEP. Results: There were 14 deaths among 707 patients (2208 postimplantation years), including 2 possible, 1 probable, and 4 definite SUDEP events. The rate of probable or definite SUDEP was 2.0/1000 (95{\%} confidence interval [CI] 0.7-5.2) over 2036 patient stimulation years and 2.3/1000 (95{\%} CI 0.9-5.4) over 2208 patient implant years. Stored electrocorticograms around the time of death were available for 4 patients with probable/definite SUDEP and revealed the following: frequent epileptiform activity ending abruptly (n = 2), no epileptiform activity or seizures (n = 1), and an electrographic and witnessed seizure with cessation of postictal electrocorticography (ECoG) activity associated with apnea and pulselessness (n = 1). Significance: The SUDEP rate of 2.0/1000 patient stimulation years among patients treated with the RNS System is favorable relative to treatment-resistant epilepsy patients randomized to the placebo arm of add-on drug studies or with seizures after resective surgery. Our findings support that treatments that reduce seizures reduce SUDEP risk and that not all SUDEPs follow seizures.",
keywords = "brain stimulation, closed-loop, neuromodulation, partial seizures, sudden unexpected death in epilepsy",
author = "Orrin Devinsky and Daniel Friedman and Duckrow, {Robert B.} and Fountain, {Nathan B.} and Gwinn, {Ryder P.} and Leiphart, {James W.} and Murro, {Anthony M} and {Van Ness}, {Paul C.}",
year = "2018",
month = "3",
day = "1",
doi = "10.1111/epi.13998",
language = "English (US)",
volume = "59",
pages = "555--561",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Sudden unexpected death in epilepsy in patients treated with brain-responsive neurostimulation

AU - Devinsky, Orrin

AU - Friedman, Daniel

AU - Duckrow, Robert B.

AU - Fountain, Nathan B.

AU - Gwinn, Ryder P.

AU - Leiphart, James W.

AU - Murro, Anthony M

AU - Van Ness, Paul C.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Objective: To study the incidence and clinical features of sudden unexpected death in epilepsy (SUDEP) in patients treated with direct brain-responsive stimulation with the RNS System. Methods: All deaths in patients treated in clinical trials (N = 256) or following U.S. Food and Drug Administration (FDA) approval (N = 451) through May 5, 2016, were adjudicated for SUDEP. Results: There were 14 deaths among 707 patients (2208 postimplantation years), including 2 possible, 1 probable, and 4 definite SUDEP events. The rate of probable or definite SUDEP was 2.0/1000 (95% confidence interval [CI] 0.7-5.2) over 2036 patient stimulation years and 2.3/1000 (95% CI 0.9-5.4) over 2208 patient implant years. Stored electrocorticograms around the time of death were available for 4 patients with probable/definite SUDEP and revealed the following: frequent epileptiform activity ending abruptly (n = 2), no epileptiform activity or seizures (n = 1), and an electrographic and witnessed seizure with cessation of postictal electrocorticography (ECoG) activity associated with apnea and pulselessness (n = 1). Significance: The SUDEP rate of 2.0/1000 patient stimulation years among patients treated with the RNS System is favorable relative to treatment-resistant epilepsy patients randomized to the placebo arm of add-on drug studies or with seizures after resective surgery. Our findings support that treatments that reduce seizures reduce SUDEP risk and that not all SUDEPs follow seizures.

AB - Objective: To study the incidence and clinical features of sudden unexpected death in epilepsy (SUDEP) in patients treated with direct brain-responsive stimulation with the RNS System. Methods: All deaths in patients treated in clinical trials (N = 256) or following U.S. Food and Drug Administration (FDA) approval (N = 451) through May 5, 2016, were adjudicated for SUDEP. Results: There were 14 deaths among 707 patients (2208 postimplantation years), including 2 possible, 1 probable, and 4 definite SUDEP events. The rate of probable or definite SUDEP was 2.0/1000 (95% confidence interval [CI] 0.7-5.2) over 2036 patient stimulation years and 2.3/1000 (95% CI 0.9-5.4) over 2208 patient implant years. Stored electrocorticograms around the time of death were available for 4 patients with probable/definite SUDEP and revealed the following: frequent epileptiform activity ending abruptly (n = 2), no epileptiform activity or seizures (n = 1), and an electrographic and witnessed seizure with cessation of postictal electrocorticography (ECoG) activity associated with apnea and pulselessness (n = 1). Significance: The SUDEP rate of 2.0/1000 patient stimulation years among patients treated with the RNS System is favorable relative to treatment-resistant epilepsy patients randomized to the placebo arm of add-on drug studies or with seizures after resective surgery. Our findings support that treatments that reduce seizures reduce SUDEP risk and that not all SUDEPs follow seizures.

KW - brain stimulation

KW - closed-loop

KW - neuromodulation

KW - partial seizures

KW - sudden unexpected death in epilepsy

UR - http://www.scopus.com/inward/record.url?scp=85040613218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040613218&partnerID=8YFLogxK

U2 - 10.1111/epi.13998

DO - 10.1111/epi.13998

M3 - Article

VL - 59

SP - 555

EP - 561

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 3

ER -